Clinical Trial

Etrasimod as Prevention of Pouchitis

Study acronym: ESPIRIT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The researchers propose conducting a multi-center, randomized, placebo-controlled study to investigate the potential role of etrasimod for the primary and secondary prevention of pouchitis among high-risk patients submitted to total proctocolectomy (TPC) with ileal-pouch anal anastomosis (IPAA) for medically refractory disease. The trial will be conducted in compliance with this protocol, Good Clinical Practice guidelines, and Institutional Review Board requirements.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-11
Trial Details
NCT Number NCT07486921
Lead Sponsor Maia Kayal
Collaborators: Pfizer
Conditions Pouchitis
Enrollment 40 participants
Start Date 2026-06-12
Primary Completion 2030-02-06 (estimated)
Study Completion 2030-02-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-10